CytomX Therapeutics Inc. (NASDAQ:CTMX) Director Ix L.P. Canaan sold 13,730 shares of the business’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $11.03, for a total transaction of $151,441.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ix L.P. Canaan also recently made the following trade(s):

  • On Monday, November 14th, Ix L.P. Canaan sold 86,270 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.16, for a total transaction of $962,773.20.

Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) opened at 11.31 on Tuesday. The stock’s market capitalization is $411.71 million. CytomX Therapeutics Inc. has a 12-month low of $9.10 and a 12-month high of $24.68. The firm’s 50-day moving average is $13.13 and its 200 day moving average is $11.73.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

A number of institutional investors have recently made changes to their positions in CTMX. Tekla Capital Management LLC raised its position in shares of CytomX Therapeutics by 130.5% in the second quarter. Tekla Capital Management LLC now owns 756,090 shares of the company’s stock valued at $7,723,000 after buying an additional 428,031 shares in the last quarter. Redmile Group LLC increased its position in shares of CytomX Therapeutics by 0.6% in the second quarter. Redmile Group LLC now owns 733,899 shares of the company’s stock valued at $7,497,000 after buying an additional 4,200 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of CytomX Therapeutics by 5.8% in the third quarter. BlackRock Fund Advisors now owns 557,851 shares of the company’s stock valued at $8,747,000 after buying an additional 30,603 shares during the last quarter. BlackRock Advisors LLC increased its position in shares of CytomX Therapeutics by 21,170.0% in the second quarter. BlackRock Advisors LLC now owns 542,384 shares of the company’s stock valued at $5,541,000 after buying an additional 539,834 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of CytomX Therapeutics by 61.5% in the second quarter. Vanguard Group Inc. now owns 371,522 shares of the company’s stock valued at $3,795,000 after buying an additional 141,466 shares during the last quarter. 51.59% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

5 Day Chart for NASDAQ:CTMX

Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.